Holen Sie sich die Stockscreener-App
0.8841
6.51%
-0.0616
Handel nachbörslich:
.89
0.0059
+0.67%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.9457
Offen:
$0.9209
24-Stunden-Volumen:
3.51M
Relative Volume:
0.27
Marktkapitalisierung:
$254.62M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.1051
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+14.77%
1M Leistung:
+41.09%
6M Leistung:
+19.72%
1J Leistung:
-47.22%
1-Tages-Spanne:
$0.855
$0.9453
1-Wochen-Bereich:
$0.7685
$0.97
52-Wochen-Spanne:
$0.2836
$2.45
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.8841 | 254.62M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener
Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus
LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals (LXRX) Reports Higher Q1 Revenue and Key Strategic Developments | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals (LXRX) Pre-Earnings Options Activity Rev - GuruFocus
LEXICON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Lexicon Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Barclays PLC - Defense World
Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlig - GuruFocus
Lexicon: Q1 Earnings Snapshot - New Haven Register
Lexicon Pharmaceuticals (LXRX) Secures Major Licensing Deal with Novo Nordisk - GuruFocus
Lexicon Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha
Earnings call transcript: Lexicon Q1 2025 beats EPS expectations, stock declines - Investing.com
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings: EPS Beats E - GuruFocus
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals Q1 Operating Income USD -25.679 Million - marketscreener.com
Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial - Stock Titan
A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals Announces Exclusive Fireside Chat at HC Wainwright BioConnect Conference - Stock Titan
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times
Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan
Carcinoid Syndrome Diarrhea Treatment Market To Reach US$ - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Lexicon Pharmaceuticals, Inc. (LXRX)Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Lead Plaintiff Deadline: April 1, 2019 - ACCESS Newswire
Top 2 Health Care Stocks That May Crash This Month - Benzinga
Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider
Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):